Login Register Cart 0
Generic placeholder image

Current Pharmaceutical Design

Editor-in-Chief

ISSN (Print): 1381-6128
ISSN (Online): 1873-4286

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
General Research Article

PHOSPHO1 Gene DNA Methylations are Associated with a Change in HDL-C Response to Simvastatin Treatment

Author(s): Juanlin Fan, Qianru Cai, Di Zhang, Justin Weinstock, Xiaoxiao Qu and Shanqun Jiang*

Volume 26, Issue 38, 2020

Page: [4944 - 4952] Pages: 9

DOI: 10.2174/1381612826666200720234604

Price: $65

Abstract

Objective: Our aim was to detect the effects of DNA methylations in the phosphoethanolamine/ phosphocholine phosphatase (PHOSPHO1) gene on the therapeutic efficacy of simvastatin.

Methods: We used an extreme sampling approach by selecting 211 individuals from approximately the top and bottom 15% of adjusted lipid-lowering response residuals to simvastatin (n=104 for the high response group and n=107 for the low response group) from a total of 734 subjects with hyperlipidemia. They received a daily oral dose of 20 mg simvastatin for eight consecutive weeks. DNA methylation loci at the PHOSPHO1 gene were measured using high-throughput next-generation sequencing-based sequencing technology. Fasting serum lipids were measured at baseline and after eight weeks of simvastatin treatment.

Results: Mean PHOSPHO1 DNA methylation had a significant negative correlation with high-density lipoprotein cholesterol (HDL-C) variation (β=-0.014, P=0.045) in the high response group. After stratifying by body mass index (BMI), the associations between the PHOSPHO1 DNA methylations and the change in HDL-C in response to simvastatin were more significant in obese subjects with a BMI of 25 kg/m2 or higher (β=-0.027, P=0.002). Mean PHOSPHO1 methylation and traditional predictors could explain up to 24.7% (adjusted R2) of the change in HDL-C response in obese patients. There was a statistically significant additive interaction term (P=0.028) between BMI and mean PHOSPHO1 methylation in the model of the change in HDL-C in response to simvastatin.

Conclusion: Our findings suggest that PHOSPHO1 DNA methylations are associated with a change in HDL-C in response to simvastatin treatment, and this association is especially dependent on the extent of patient obesity.

Keywords: PHOSPHO1, DNA methylation, Hyperlipidemia, Simvastatin, lipoprotein, phosphocholine.

« Previous
[1]
Thomas H, Diamond J, Vieco A, et al. Global atlas of cardiovascular disease 2000-2016: The path to prevention and control. Glob Heart 2018; 13(3): 143-63.
[http://dx.doi.org/10.1016/j.gheart.2018.09.511 ] [PMID: 30301680]
[2]
Cole CB, Nikpay M, McPherson R. Gene-environment interaction in dyslipidemia. Curr Opin Lipidol 2015; 26(2): 133-8.
[http://dx.doi.org/10.1097/MOL.0000000000000160 ] [PMID: 25692343]
[3]
Willer CJ, Schmidt EM, Sengupta S, et al. Global lipids genetics consortium. Discovery and refinement of loci associated with lipid levels. Nat Genet 2013; 45(11): 1274-83.
[http://dx.doi.org/10.1038/ng.2797 ] [PMID: 24097068]
[4]
Pfeiffer L, Wahl S, Pilling LC, et al. DNA methylation of lipid-related genes affects blood lipid levels. Circ Cardiovasc Genet 2015; 8(2): 334-42.
[http://dx.doi.org/10.1161/CIRCGENETICS.114.000804 ] [PMID: 25583993]
[5]
Guay SP, Voisin G, Brisson D, et al. Epigenome-wide analysis in familial hypercholesterolemia identified new loci associated with high-density lipoprotein cholesterol concentration. Epigenomics 2012; 4(6): 623-39.
[http://dx.doi.org/10.2217/epi.12.62 ] [PMID: 23244308]
[6]
Kim M, Costello J. DNA methylation: an epigenetic mark of cellular memory. Exp Mol Med 2017; 49(4) e322
[http://dx.doi.org/10.1038/emm.2017.10 ] [PMID: 28450738]
[7]
Nazarenko MS, Markov AV, Lebedev IN, et al. A comparison of genome-wide DNA methylation patterns between different vascular tissues from patients with coronary heart disease. PLoS One 2015; 10(4) e0122601
[http://dx.doi.org/10.1371/journal.pone.0122601 ] [PMID: 25856389]
[8]
Guay SP, Brisson D, Lamarche B, Gaudet D, Bouchard L. Epipolymorphisms within lipoprotein genes contribute independently to plasma lipid levels in familial hypercholesterolemia. Epigenetics 2014; 9(5): 718-29.
[http://dx.doi.org/10.4161/epi.27981 ] [PMID: 24504152]
[9]
Roberts SJ, Stewart AJ, Sadler PJ, Farquharson C. Human PHOSPHO1 exhibits high specific phosphoethanolamine and phosphocholine phosphatase activities. Biochem J 2004; 382(Pt 1): 59-65.
[http://dx.doi.org/10.1042/BJ20040511 ] [PMID: 15175005]
[10]
Kiffer-Moreira T, Yadav MC, Zhu D, et al. Pharmacological inhibition of PHOSPHO1 suppresses vascular smooth muscle cell calcification. J Bone Miner Res 2013; 28(1): 81-91.
[http://dx.doi.org/10.1002/jbmr.1733 ] [PMID: 22887744]
[11]
Chambers JC, Loh M, Lehne B, et al. Epigenome-wide association of DNA methylation markers in peripheral blood from Indian Asians and Europeans with incident type 2 diabetes: a nested case-control study. Lancet Diabetes Endocrinol 2015; 3(7): 526-34.
[http://dx.doi.org/10.1016/S2213-8587(15)00127-8 ] [PMID: 26095709]
[12]
Sayols-Baixeras S, Subirana I, Lluis-Ganella C, et al. Identification and validation of seven new loci showing differential DNA methylation related to serum lipid profile: an epigenome-wide approach. The REGICOR study. Hum Mol Genet 2016; 25(20): 4556-65.
[http://dx.doi.org/10.1093/hmg/ddw285 ] [PMID: 28173150]
[13]
Dayeh T, Tuomi T, Almgren P, et al. DNA methylation of loci within ABCG1 and PHOSPHO1 in blood DNA is associated with future type 2 diabetes risk. Epigenetics 2016; 11(7): 482-8.
[http://dx.doi.org/10.1080/15592294.2016.1178418 ] [PMID: 27148772]
[14]
Vaughan CJ, Gotto AM Jr. Update on statins: 2003. Circulation 2004; 110(7): 886-92.
[http://dx.doi.org/10.1161/01.CIR.0000139312.10076.BA ] [PMID: 15313959]
[15]
Voora D, Shah SH, Reed CR, et al. Pharmacogenetic predictors of statin-mediated low-density lipoprotein cholesterol reduction and dose response. Circ Cardiovasc Genet 2008; 1(2): 100-6.
[http://dx.doi.org/10.1161/CIRCGENETICS.108.795013 ] [PMID: 20031551]
[16]
van Venrooij FV, Stolk RP, Banga JD, et al. DALI Study Group. Common cholesteryl ester transfer protein gene polymorphisms and the effect of atorvastatin therapy in type 2 diabetes. Diabetes Care 2003; 26(4): 1216-23.
[http://dx.doi.org/10.2337/diacare.26.4.1216 ] [PMID: 12663600]
[17]
Xu Y, Wang Y, Zhi J, Qi L, Zhang T, Li X. Impact of matrix metalloproteinase 9 rs3918242 genetic variant on lipid-lowering efficacy of simvastatin therapy in Chinese patients with coronary heart disease. BMC Pharmacol Toxicol 2017; 18(1): 28.
[http://dx.doi.org/10.1186/s40360-017-0132-y ] [PMID: 28390432]
[18]
Jiang S, Chen Q, Venners SA, et al. Effect of simvastatin on plasma homocysteine levels and its modification by MTHFR C677T polymorphism in Chinese patients with primary hyperlipidemia. Cardiovasc Ther 2013; 31(4): e27-33.
[http://dx.doi.org/10.1111/1755-5922.12002 ] [PMID: 23865383]
[19]
Karr S. Epidemiology and management of hyperlipidemia. Am J Manag Care 2017; 23(9)(Suppl.): S139-48.
[PMID: 28978219]
[20]
Mangravite LM, Thorn CF, Krauss RM. Clinical implications of pharmacogenomics of statin treatment. Pharmacogenomics J 2006; 6(6): 360-74.
[http://dx.doi.org/10.1038/sj.tpj.6500384 ] [PMID: 16550210]
[21]
Mittelstraß K, Waldenberger M. DNA methylation in human lipid metabolism and related diseases. Curr Opin Lipidol 2018; 29(2): 116-24.
[http://dx.doi.org/10.1097/MOL.0000000000000491 ] [PMID: 29517982]
[22]
van der Veen JN, Kennelly JP, Wan S, Vance JE, Vance DE, Jacobs RL. The critical role of phosphatidylcholine and phosphatidylethanolamine metabolism in health and disease. Biochim Biophys Acta Biomembr 2017; 1859(9 Pt B): 1558-72.
[http://dx.doi.org/10.1016/j.bbamem.2017.04.006 ] [PMID: 28411170]
[23]
Jacobs RL, Lingrell S, Zhao Y, Francis GA, Vance DE. Hepatic CTP:phosphocholine cytidylyltransferase-alpha is a critical predictor of plasma high density lipoprotein and very low density lipoprotein. J Biol Chem 2008; 283(4): 2147-55.
[http://dx.doi.org/10.1074/jbc.M706628200 ] [PMID: 18042552]
[24]
Wang H, Liu L, Lin JZ, Aprahamian TR, Farmer SR. Browning of white adipose tissue with roscovitine induces a distinct population of UCP1+ Adipocytes. Cell Metab 2016; 24(6): 835-47.
[http://dx.doi.org/10.1016/j.cmet.2016.10.005 ] [PMID: 27974179]

Rights & Permissions Print Cite
Article Metrics
10
1
© 2024 Bentham Science Publishers | Privacy Policy